Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ
Published in Journal of Clinical Endocrinology and Metabolism
Methodology
TROPOS: 3-year randomized, double-blind, placebo-controlled trial of strontium ranelate in 5,091 postmenopausal women at risk of peripheral fracture.
Key Findings
Nonvertebral fracture risk fell by 16%, and hip fracture risk by 36% in the high-risk subgroup.
Conclusions
Strontium ranelate reduces nonvertebral fracture risk in postmenopausal osteoporosis.
Limitations
Hip fracture benefit was a post hoc high-risk subgroup finding; industry sponsored.
Supplements Studied
Strontium ranelate reduces nonvertebral fracture risk in postmenopausal osteoporosis.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.